The University of Arkansas Medical Sciences (UAMS) has received a record $38.8 million during the pandemic, primarily via state and federal sources as the academic medical center’s research resources are mobilized to take on COVID-19. Funding originated primarily from the state ($16.3m) and federal government ($19.2m). This funding supports a number of research initiatives from statewide antibody testing and multisite clinical trials investigating novel treatments to education and prevention efforts, mental health and more. UAMS Vice Chancellor for Research, Shuk-Mei Ho, PhD, reports, “This remarkable level of support from outside UAMS is a testament to the knowledge, talent and dedication of our research teams.” Dr. Ho emphasized her appreciation for just how rapidly UAMS researchers mobilized to pursue the right against COVID-19.
In addition to the major state and federal grants, UAMS was able to secure about $1.7 million for seven of 18 clinical trials thus far, or about $242,857 per study. Nonprofit organizations have kicked in $675,201 for four studies. But UAMS has invested internally—Dr Ho’s own Division of Research and Innovation invested $331,396 in nine COVID-19 pilot research projects.
UAMS Research Gets Busy
Much of this success has been the result of a series of infrastructure investments, which opened up capacity thanks to its Translational Research Institute. By 2019, this institute received a five-year, $24.2 million Clinical and Translational Science Award (CTSA) from the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).
These CTSA awards only go to the highest performing research institutions in America, and such awards bring new research opportunities, attract new collaborators and industry partners and of course and importantly, research talent.
Overall, since the onset of the pandemic UAMS has assisted with 88 COVID-19 trials. For a list of example studies, follow the link to UAMS News.